NCT02208934已完成1 期
Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau2 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2014年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 2
- 主要终点
- Number of Participants with Serious and Non-Serious Adverse Events
研究概览
简要总结
Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects, 18-45 years (inclusive) of age at the time of enrollment.
- •Males should agree to abstain from sexual intercourse with a female partner or agree to use a condom with spermicide, in addition to having their female partner use some contraceptive measures until 28 days post-administration.
- •Clinically acceptable blood pressure and pulse rate in supine and standing position. Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.
- •Body weight within normal range (Quetelet's index between 19 and 26) expressed as weight (kg) / height (m2).
- •Able to understand the nature of the study and comply with all their requirements.
- •Free acceptance to participate in the study by obtains signed informed consent form approved by the Ethics Committee of the Hospital (CEIC).
排除标准
- •History of serious adverse reactions or hypersensitivity to any drug.
- •Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).
- •Background or clinical evidence of chronic diseases.
- •Acute illness two weeks before drug administration.
- •Having undergone major surgery during the previous 6 months.
- •Smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the administration of the study medication.
- •History of alcohol dependence or drug abuse in the last 5 years or daily consumption of alcohol > 40 g or high consumption of stimulating beverages (> 5 coffees, teas or coca cola drinks/ day).
- •Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.
- •Need of any prescription medication within 14 days prior to the administration of the drug and non prescription medication or herbal medicines within 7 days prior to the administration of the drug.
- •Participation in other clinical trials during the previous 90 days in which an investigational drug or a commercially available drug was tested.
- •Having donated blood during 4 weeks period before inclusion in the study.
- •Existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the drug, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract.
- •12 lead ECG obtained at screening with PR ≥ 220 msec, QRS ≥120 msec and QTc ≥ 440 msec, bradycardia (<50 bpm) or clinically significant minor ST wave changes or any other abnormal changes on the screening ECG that would interfere with measurement of the QT interval.
- •Symptoms of a significant somatic or mental illness in the four week period preceding drug administration.
- •History of hepatitis HBV and / or HCV and / or positive serology results which indicate the presence of hepatitis B surface antigen and / or detectable HCV ribonucleic acid (RNA).
- •Positive results from the HIV serology.
- •Clinically significant abnormal laboratory values (as determined by the Principal Investigator) at the screening evaluation.
- •Positive results of the drugs at screening period or the day before starting treatment period. A minimum list of 6 drugs will be screened for inclusion: Amphetamines, Cocaine, Ethanol, Opiates, Cannabinoids and Benzodiazepines (positive results may be repeated at the discretion of the Principal Investigator).
- •Known hypersensitivity to the study drug or the composition of the galenical form.
- •History of psychiatric diseases or epileptic seizures.
研究组 & 干预措施
PBF-999 (5 mg)
Experimental
5 mg of PBF-999
干预措施: PBF-999 (Drug)
PBF-999 (10 mg)
Experimental
10 mg of PBF-999
干预措施: PBF-999 (Drug)
PBF-999 (20 mg)
Experimental
20 mg of PBF-999
干预措施: PBF-999 (Drug)
PBF-999 (40 mg)
Experimental
40 mg of PBF-999
干预措施: PBF-999 (Drug)
Placebo
Placebo Comparator
Placebo for the 5, 10, 20 and 40 mg dose
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants with Serious and Non-Serious Adverse Events
时间窗: day 0 to day 7
Vital Signs, ECG recordings, laboratory safety test and physical examination will be performed
次要结局
- Pharmacokinetic Profile Analysis (Plasma concentrations)(day 1)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy VolunteersHuntington DiseaseNCT02907294Palobiofarma SL8
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809HealthyNCT02068690Boehringer Ingelheim83
已完成
1 期
Safety, Tolerability and Pharmacodynamics After Oral Administration of BIIF 1149 BS in Healthy Male VolunteersHealthyNCT02209714Boehringer Ingelheim24
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male SubjectsHealthyNCT02184338Boehringer Ingelheim48
已完成
1 期
Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531Alzheimer DiseaseNCT00726115Wyeth is now a wholly owned subsidiary of Pfizer56